Evidence map›Paper›PMID 29151523›Full record

ArticleInternal medicine (Tokyo, Japan)2018

Neuroendocrine Carcinoma of the Stomach: A Response to Combination Chemotherapy Consisting of Ramucirumab Plus Paclitaxel.

Yuki Matsubara, Takayuki Ando, Ayumu Hosokawa, Hiroshi Mihara, Hiroaki Takagi, Naokatsu Nakata, Hiroki Yoshita, Sohachi Nanjo, Shinya Kajiura, Haruka Fujinami and 1 more

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Internal medicine (Tokyo, Japan), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors.

Yuki MatsubaraDepartment of Gastroenterology and Hematology, Faculty of Medicine, University of Toyama, Japan.
Takayuki AndoDepartment of Gastroenterology and Hematology, Faculty of Medicine, University of Toyama, Japan.
Ayumu HosokawaDepartment of Gastroenterology and Hematology, Faculty of Medicine, University of Toyama, Japan.
Hiroshi MiharaDepartment of Gastroenterology and Hematology, Faculty of Medicine, University of Toyama, Japan.
Hiroaki TakagiDepartment of Gastroenterology and Hematology, Faculty of Medicine, University of Toyama, Japan.
Naokatsu NakataDepartment of Gastroenterology and Hematology, Faculty of Medicine, University of Toyama, Japan.
Hiroki YoshitaDepartment of Gastroenterology and Hematology, Faculty of Medicine, University of Toyama, Japan.
Sohachi NanjoDepartment of Gastroenterology and Hematology, Faculty of Medicine, University of Toyama, Japan.
Shinya KajiuraDepartment of Gastroenterology and Hematology, Faculty of Medicine, University of Toyama, Japan.
Haruka FujinamiDepartment of Gastroenterology and Hematology, Faculty of Medicine, University of Toyama, Japan.
Toshiro SugiyamaDepartment of Gastroenterology and Hematology, Faculty of Medicine, University of Toyama, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Extrapulmonary neuroendocrine carcinoma (NEC) is a rare disease, and there is no standard chemotherapy. A 73-year-old man was diagnosed with advanced gastric NEC. He received chemotherapy of irinotecan plus cisplatin, and amrubicin monotherapy. After failure of second-line chemotherapy, he received ramucirumab plus paclitaxel; this treatment was chosen because vascular endothelial growth factor 2 was strongly expressed in the tumor endothelial cells. After two cycles, his NEC had markedly reduced in size, and he continued with this treatment for over eight months. In this case, the combination of an anti-angiogenic inhibitor and a cytotoxic agent was highly effective for gastric NEC.

Indexed as

AgedAnthracyclinesAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsCamptothecinCarcinoma, NeuroendocrineCisplatinHumansIrinotecanMalePaclitaxelRamucirumabStomach NeoplasmsamrubicinAnthracyclinesAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic AgentsCamptothecinCisplatinIrinotecanPaclitaxelRamucirumabchemotherapyneuroendocrine carcinomapaclitaxelramucirumabVEGFR2

Identifiers

PMID29151523
PMCPMC5874337

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.